Home
Random
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
Evgen Pharma plc
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Summary<ref>Source: Yahoo Finance.</ref> == Evgen Pharma plc, a clinical stage drug development company, focuses on the development of sulforaphane-based medicines for the treatment of cancer and inflammatory diseases. It develops its products using Sulforadex, a sulforaphane stabilization technology. The company's lead product is SFX-01, that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase Ib/IIa clinical trials for the treatment of glioblastoma, as well as in preclinical stage for the treatment of haematological malignancies and analogues. It also provides out-licensing of its technology services. Evgen Pharma plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom. == References and notes == [[Category:Thesis]] __INDEX__
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
